Company’s Q3-2020 (Jul-Sep) operating results based on its reviewed consolidated financial statements ended 30 Sep 2020 as follows. Highlights on Q3-2020 Operating Results Unit : Million Baht Q3-20 Q3-19 Q2
Q1-2021 (Jan-Mar) operating results based on its reviewed consolidated financial statements ended 31 March 2021 as follows. Highlights on Q1-2021 Operating Results Unit : Million Baht Q1-21 Q1-20 Q4-20
10,002,000 shares from the additional new shares of Sakun C Innovation Company Limited, equivalent to 100,020,000 baht. After the transaction is completed, the Company will hold 50.01% of the shares in SKC
Q1-2020 (Jan-Mar) operating results based on its reviewed consolidated financial statements ended 31 March 2020 as follows. Highlights on Q1-2020 Operating Results Unit : Million Baht Q1-20 Q1-19 Q4-19
consolidated financial statements for the 3-month period as of March 31, 2019, 1) Calculate the size of transaction 6 months backward which include waiver of rights to purchase the new ordinary shares of Rich
opportunity in the future of the company And is a new way to increase revenue. The opinions of the Audit Committee and / or the directors that are different from the opinions of the Board of Directors -None
follows: (Since the consolidated financial statements included the accounts of the Company and its subsidiaries which the operation of subsidiaries have not yet significant, the Management Discussion and
consolidated financial statements of Q1/2024 compared to the same period of the year 2023, is as follows: Total Revenue amounted to THB 3,568.38 million increased by 3.23% Gross Profit amounted to THB 334.25
-month and 6-month period ended 30 June 2019 compared to the same period last year. In the consolidated financial statements for 3-month period ended 30 June 2019, the total revenue of Golden Lime and its
Discussion and Analysis (MD&A) Consolidated Financial Results: 1Q20 Major Events Performance Business Plan Document Quick Link Central Pattana Public Company Limited Management’s Discussion and Analysis (MD&A